Literature DB >> 1326134

Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions.

M Siebels1, K Andrassy, P Vecsei, H P Seelig, T Back, P Nawroth, E Weber.   

Abstract

One neglected side effect of heparin therapy is the inhibition of adrenal aldosterone production leading to occasionally life-threatening hyperkalaemia. This is only reported with (therapeutic) high doses (greater than or equal to 20.000 IU). The complex interplay of mineralocorticoid metabolites was studied in 29 subjects with unfractionated (UFH) and low molecular weight heparin (LMWH). Both heparins altered mineralocorticoid metabolism in a dose dependent manner. Whereas no effect was observed with UFH 2 x 5000 IU sc/day or LMWH 2500 a FXa U sc/day, higher doses significantly suppressed aldosterone and 18-hydroxycorticosterone production in plasma and urine. Three out of seven patients receiving UFH 3 x 7500 IU sc/day developed hyperkalaemia. This study shows the threshold dosage of UFH leading to suppression of mineralocorticoid metabolism in man and provides information that LMWH as well as UFH can suppress mineralocorticoid production. With respect to therapeutic implications it is important that LMWH at 2500 a FXa U sc/d had no effect on mineralocorticoid metabolism in contrast to UFH at a dosage currently used for prevention of thromboembolism (3 x 5000 IU sc/d).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326134     DOI: 10.1016/0049-3848(92)90301-p

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Effect of prophylactic treatment with low-molecular-weight heparin bemiparin sodium on serum potassium levels: a prospective observational study.

Authors:  Olga H Torres; Nerea Hernandez; Esther Francia; Montserrat Barcelo; Jose Mateo; Domingo Ruiz
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Drug-induced hyperkalemia.

Authors:  Chaker Ben Salem; Atef Badreddine; Neila Fathallah; Raoudha Slim; Houssem Hmouda
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

3.  Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.

Authors:  Giuseppe Gheno; Leonardo Cinetto; Carmelo Savarino; Sandro Vellar; Maurizio Carraro; Massimo Randon
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

4.  Heparin-induced hyperkalemia in an extremely-low-birth-weight infant: a case report.

Authors:  Tomoyuki Shimokaze; Kazuhiro Akaba; Emi Saito
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014

5.  Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.

Authors:  Nima Melzer; Peter Bramlage; Hans-Christoph Michaelis
Journal:  BMC Res Notes       Date:  2014-12-06

6.  Heparin-Induced Hyperkalemia in a Dog Receiving Continuous Renal Replacement Treatment.

Authors:  B Geesaman; J Bach; K Monaghan
Journal:  J Vet Intern Med       Date:  2015-10-08       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.